Table 1.
Data of treated patients who underwent SIRT in March–July period: comparison between 2019 and 2020.
| 2019 | 2020 | p | ||
|---|---|---|---|---|
| Number of patients | 22 | 36 | ||
| Gender | Male | 16 (72.7) | 27 (75.0) | 0.85 |
| Age (years) | Mean ± SD | 68.8 ± 10.6 | 67.1 ± 11.1 | 0.55 |
| Type of tumor | Primary | 14 (63.6) | 27 (75.0) | 0.36 |
| Metastatic | 8 (36.4) | 9 (25.0) | ||
| Histotype | HCC | 12 (54.5) | 22 (61.1) | 0.51 |
| ICC | 2 (9.1) | 5 (13.9) | ||
| mCRC | 6 (27.3) | 6 (16.7) | ||
| Other | 2 (9.1) * | 3 (8.3) ** | ||
| BCLC staging (HCC) | A | 3 (25) | 0 (0) | 0.04 |
| B | 6 (50) | 14 (63.6) | ||
| C | 3 (25) | 8 (36.4) | ||
| TNM staging (iCC) | III | 0 (0) | 4 (80) | 0.03 |
| IVa | 2 (100) | 0 (0) | ||
| IVb | 0 (0) | 1 (20) | ||
| Treatment line (metastases) | First | 2 (25) | 0 (0) | 0.23 |
| Second | 3 (37.5) | 3 (33.3) | ||
| Third | 3 (37.5) | 6 (66.7) | ||
| Type of procedure | Segmental | 2 (9.1) | 4 (11.1) | 0.78 |
| Unilobar | 16 (72.7) | 23 (63.9) | ||
| Bilobar | 4 (18.2) | 9 (25) | ||
| Type of spheres | Yttrium-90 resin | 18 (81.8) | 26 (72.2) | 0.57 |
| Yttrium-90 glass | 2 (9.1) | 3 (8.3) | ||
| Holmium-166 | 2 (9.1) | 7 (19.5) |
When not otherwise specified, data are given as numbers (and percentages). * Includes: neuroendocrine tumor (n = 1) and medullary thyroid carcinoma (n = 1). ** Includes: renal cell carcinoma (n = 1), uveal melanoma (n = 1) and lung cancer (n = 1).